Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans
- PMID: 17497628
- PMCID: PMC6870740
- DOI: 10.1002/hbm.20392
Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans
Abstract
The D(2) receptors exist in either the high- or low-affinity state with respect to agonists, and while agonists bind preferentially to the high-affinity state, antagonists do not distinguish between the two states. [(11)C]-(+)-PHNO is a PET D(2) agonist radioligand and therefore provides a preferential measure of the D(2) (high) receptors. In contrast, [(11)C]raclopride is an antagonist radioligand and thus binds with equal affinity to the D(2) high- and low-affinity states. The aim was to compare the brain uptake, distribution and binding characteristics between [(11)C]-(+)-PHNO and [(11)C]raclopride in volunteers using a within-subject design. Both radioligands accumulated in brain areas rich in D(2)/D(3)-receptors. However, [(11)C]-(+)-PHNO showed preferential uptake in the ventral striatum and globus pallidus, while [(11)C]raclopride showed preferential uptake in the dorsal striatum. Mean binding potentials were higher in the putamen (4.3 vs. 2.8) and caudate (3.4 vs 2.1) for [(11)C]raclopride, equal in the ventral-striatum (3.4 vs. 3.3), and higher in the globus pallidus for [(11)C]-(+)-PHNO (1.8 vs. 3.3). Moreover [(11)C]-(+)-PHNO kinetics in the globus pallidus showed a slower washout than other regions. One explanation for the preferential binding of [(11)C]-(+)-PHNO in the globus pallidus and ventral-striatum could be the presence of a greater proportion of high- vs. low-affinity receptors in these areas. Alternatively, the observed distribution could also be explained by a preferential binding of D(3)-over-D(2) with [(11)C]-(+)-PHNO. This differential binding of agonist vs. antagonist radioligand, especially in the critically important region of the limbic striatum/pallidum, offers new avenues to investigate the role of the dopamine system in health and disease.
(c) 2007 Wiley-Liss, Inc.
Figures




Similar articles
-
Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography.J Neurochem. 2006 May;97(4):1089-103. doi: 10.1111/j.1471-4159.2006.03840.x. Epub 2006 Apr 5. J Neurochem. 2006. PMID: 16606355
-
The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.Arch Gen Psychiatry. 2009 Jun;66(6):606-15. doi: 10.1001/archgenpsychiatry.2009.43. Arch Gen Psychiatry. 2009. PMID: 19487625 Clinical Trial.
-
Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo.Synapse. 2006 Dec 1;60(7):485-95. doi: 10.1002/syn.20325. Synapse. 2006. PMID: 16952157
-
[11C](+)-4-N-Propyl-,3,4a,5,6,10b-hexahydro-2H-naphth[1,2-b][1,4]-oxazin-9-ol.2006 May 2 [updated 2011 Oct 6]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2006 May 2 [updated 2011 Oct 6]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641608 Free Books & Documents. Review.
-
Measuring amphetamine-induced dopamine release in humans: A comparative meta-analysis of [11 C]-raclopride and [11 C]-(+)-PHNO studies.Synapse. 2021 May;75(5):e22195. doi: 10.1002/syn.22195. Epub 2021 Feb 1. Synapse. 2021. PMID: 33471400 Review.
Cited by
-
DRD2 Genotype-Based Variants Modulates D2 Receptor Distribution in Ventral Striatum.Mol Neurobiol. 2019 Sep;56(9):6512-6520. doi: 10.1007/s12035-019-1543-0. Epub 2019 Mar 8. Mol Neurobiol. 2019. PMID: 30847741
-
Ventral striatum binding of a dopamine D2/3 receptor agonist but not antagonist predicts normal body mass index.Biol Psychiatry. 2015 Jan 15;77(2):196-202. doi: 10.1016/j.biopsych.2013.02.017. Epub 2013 Mar 27. Biol Psychiatry. 2015. PMID: 23540907 Free PMC article.
-
The relationship between glutamate, dopamine, and cortical gray matter: A simultaneous PET-MR study.Mol Psychiatry. 2022 Aug;27(8):3493-3500. doi: 10.1038/s41380-022-01596-6. Epub 2022 May 11. Mol Psychiatry. 2022. PMID: 35546633 Free PMC article. Clinical Trial.
-
Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.Naunyn Schmiedebergs Arch Pharmacol. 2013 Feb;386(2):155-66. doi: 10.1007/s00210-012-0806-3. Epub 2012 Nov 6. Naunyn Schmiedebergs Arch Pharmacol. 2013. PMID: 23128852 Review.
-
The Impact of Muscarinic Antagonism on Psychosis-Relevant Behaviors and Striatal [11C] Raclopride Binding in Tau Mouse Models of Alzheimer's Disease.Biomedicines. 2023 Jul 25;11(8):2091. doi: 10.3390/biomedicines11082091. Biomedicines. 2023. PMID: 37626588 Free PMC article.
References
-
- Camps M,Cortes R,Gueye B,Probst A,Palacios JM ( 1989): Dopamine receptors in human brain: Autoradiographic distribution of D2 sites. Neuroscience 28: 275–290. - PubMed
-
- De Keyser J,De Backer JP,Convents A ( 1985): D2 dopamine receptors in calf globus pallidus: Agonist high‐ and low‐affinity sites not regulated by guanine nucleotide. J Neurochem 45: 977–978. - PubMed
-
- De Keyser J,Claeys A,De Backer JP,Ebinger G,Roels F,Vauquelin G ( 1988): Autoradiographic localization of D1 and D2 dopamine receptors in the human brain. Neurosci Lett 91: 142–147. - PubMed
-
- De Lean A,Stadel JM,Lefkowitz RJ ( 1980): A ternary complex model explains the agonist‐specific binding properties of the adenylate cyclase‐coupled beta‐adrenergic receptor. J Biol Chem 255: 7108–7117. - PubMed
-
- de Vries DJ,Beart PM ( 1986): Role of assay conditions in determining agonist potency at D2 dopamine receptors in striatal homogenates. Brain Res 387: 29–35. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources